- Home
- CFFI vs NBP Comparison
CFFI vs NBP Comparison
Compare CFFI & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFFI | NBP |
|---|---|---|
| Founded | 1927 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.9M | 275.2M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | CFFI | NBP |
|---|---|---|
| Price | $74.38 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 2.1K | ★ 1.1M |
| Earning Date | 04-23-2026 | 04-07-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ 37.94 | N/A |
| EPS | ★ 8.29 | N/A |
| Revenue | ★ $140,841,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.94 | ★ N/A |
| Revenue Growth | ★ 10.63 | N/A |
| 52 Week Low | $58.00 | $2.10 |
| 52 Week High | $80.99 | $5.19 |
Technical Indicators
Market Signals| Indicator | CFFI | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 44.10 | 29.79 |
| Support Level | $66.92 | N/A |
| Resistance Level | $79.57 | $2.73 |
| Average True Range (ATR) | 1.32 | 0.15 |
| MACD | -0.35 | -0.02 |
| Stochastic Oscillator | 30.97 | 2.54 |
Price Performance
Historical ComparisonAbout CFFI C&F Financial Corporation
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.